List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4810424/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Methodology and Indications of H ₂ â€Breath Testing in Gastrointestinal Diseases: the Rome Consensus Conference. Alimentary Pharmacology and Therapeutics, 2009, 29, 1-49.	1.9	320
2	Evidence for the Presence of Non-Celiac Gluten Sensitivity in Patients with Functional Gastrointestinal Symptoms: Results from a Multicenter Randomized Double-Blind Placebo-Controlled Gluten Challenge. Nutrients, 2016, 8, 84.	1.7	155
3	Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. European Journal of Endocrinology, 2005, 152, 443-448.	1.9	94
4	Randomised controlled trial of mesalazine in IBS. Gut, 2016, 65, 82-90.	6.1	91
5	Chronic constipation: A critical review. Digestive and Liver Disease, 2013, 45, 886-893.	0.4	87
6	The Role of Ultrasound Elasticity Imaging in Predicting Ileal Fibrosis in Crohn's Disease Patients. Inflammatory Bowel Diseases, 2015, 21, 2605-2612.	0.9	73
7	European guideline on indications, performance, and clinical impact of hydrogen and methane breath tests in adult and pediatric patients: European Association for Gastroenterology, Endoscopy and Nutrition, European Society of Neurogastroenterology and Motility, and European Society for Paediatric Gastroenterology Hepatology and Nutrition consensus. United European Gastroenterology	1.6	64
8	Journal, 2022, 10, 153-10. Loss of interstitial cells and a fibromuscular layer on the luminal side of the colonic circular muscle presenting as megacolon in an adult patient. Gut, 1999, 45, 775-779.	6.1	63
9	Reduction of CD68+ Macrophages and Decreased IL-17 Expression in Intestinal Mucosa of Patients with Inflammatory Bowel Disease Strongly Correlate With Endoscopic Response and Mucosal Healing following Infliximab Therapy. Inflammatory Bowel Diseases, 2013, 19, 729-739.	0.9	62
10	Assessing the activity of perianal Crohn's disease: Comparison of clinical indices and computer-assisted anal ultrasound. Inflammatory Bowel Diseases, 2009, 15, 742-749.	0.9	56
11	Constipation severity is associated with productivity losses and healthcare utilization in patients with chronic constipation. United European Gastroenterology Journal, 2014, 2, 138-147.	1.6	56
12	Ultrasound Elasticity Imaging Predicts Therapeutic Outcomes of Patients With Crohn's Disease Treated With Anti-Tumour Necrosis Factor Antibodies. Journal of Crohn's and Colitis, 2018, 12, 63-70.	0.6	56
13	Oral naloxone antagonizes loperamide-induced delay of orocecal transit. Digestive Diseases and Sciences, 1987, 32, 829-832.	1.1	55
14	Effect of loperamide and naloxone on mouth-to-caecum transit time evaluated by lactulose hydrogen breath test Gut, 1985, 26, 700-703.	6.1	54
15	The use of methotrexate for treatment of inflammatory bowel disease in clinical practice. Digestive and Liver Disease, 2012, 44, 123-127.	0.4	52
16	Anorectal dysfunction and delayed colonic transit in patients with progressive systemic sclerosis. Digestive Diseases and Sciences, 1993, 38, 1525-1529.	1.1	47
17	Is the subjective perception of lactose intolerance influenced by the psychological profile?. Alimentary Pharmacology and Therapeutics, 2012, 36, 660-669.	1.9	47
18	Functional gastrointestinal and somatoform symptoms five months after SARSâ€CoVâ€2 infection: A controlled cohort study. Neurogastroenterology and Motility, 2022, 34, e14187.	1.6	45

#	Article	IF	CITATIONS
19	Highâ€resolution anorectal manometry: An expensive hobby or worth every penny?. Neurogastroenterology and Motility, 2017, 29, e13125.	1.6	44
20	Orocecal transit delay in obese patients. Digestive Diseases and Sciences, 1989, 34, 509-512.	1.1	41
21	Rectal hyperreactivity to distention in patients with irritable bowel syndrome: role of distention rate. Clinical Gastroenterology and Hepatology, 2004, 2, 49-56.	2.4	40
22	Sensations induced by medium and long chain triglycerides: role of gastric tone and hormones. Gut, 2000, 46, 32-36.	6.1	37
23	Confirmatory factor analysis of the Patient Assessment of Constipation-Symptoms (PAC-SYM) among patients with chronic constipation. Quality of Life Research, 2015, 24, 1597-1605.	1.5	35
24	Gastrointestinal symptoms impair quality of life in Italian renal transplant recipients but are under-recognized by physicians. Transplant International, 2010, 23, 1126-1134.	0.8	34
25	Computer-Assisted Evaluation of Perianal Fistula Activity by Means of Anal Ultrasound in Patients with Crohn's Disease. American Journal of Gastroenterology, 2006, 101, 1551-1558.	0.2	31
26	Bloating is associated with worse quality of life, treatment satisfaction, and treatment responsiveness among patients with constipationâ€predominant irritable bowel syndrome and functional constipation. Neurogastroenterology and Motility, 2016, 28, 581-591.	1.6	30
27	Treatment of 'cimetidine-resistant' chronic duodenal ulcers with ranitidine or cimetidine: a randomised multicentre study Gut, 1984, 25, 1113-1117.	6.1	29
28	Repeatability of lactulose hydrogen breath test in subjects with normal or prolonged orocecal transit. Digestive Diseases and Sciences, 1988, 33, 1525-1527.	1.1	23
29	Discrepancy between recalled and recorded bowel habits in irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2010, 32, 282-288.	1.9	23
30	Patient dissatisfaction with medical therapy for chronic constipation or irritable bowel syndrome with constipation: analysis of Nâ€ofâ€1 prospective trials in 81 patients. Alimentary Pharmacology and Therapeutics, 2020, 51, 629-636.	1.9	23
31	Cerebellar degeneration and hearing loss in a patient with idiopathic myenteric ganglionitis. European Journal of Gastroenterology and Hepatology, 2005, 17, 449-452.	0.8	22
32	Review of the indications, methods, and clinical utility of anorectal manometry and the rectal balloon expulsion test. Neurogastroenterology and Motility, 2022, 34, e14335.	1.6	22
33	Oesophageal manometry in the evaluation of megacolon with onset in adult life Gut, 1997, 40, 188-191.	6.1	20
34	Abdominal distension after colonic lactulose fermentation recorded by a new extensometer. Neurogastroenterology and Motility, 2003, 15, 427-433.	1.6	20
35	Acid clearance and oesophageal sensitivity in patients with progressive systemic sclerosis Gut, 1993, 34, 1487-1491.	6.1	19
36	Postprandial Gut Peptide Plasma Levels in Women with Idiopathic Slow-Transit Constipation. Scandinavian Journal of Gastroenterology, 1999, 34, 25-28.	0.6	19

#	Article	IF	CITATIONS
37	Perceptual sensitivity and response bias during rectal distension in patients with irritable bowel syndrome1. Neurogastroenterology and Motility, 2005, 17, 541-547.	1.6	18
38	Bowel Urgency in Patients With Irritable Bowel Syndrome. Gastroenterology, 2007, 132, 38-44.	0.6	17
39	lleal distention relaxes the canine colon: A model of megacolon?. Gastroenterology, 1994, 106, 606-614.	0.6	16
40	Magnetic Resonance Imaging of the Rectum During Distension. Diseases of the Colon and Rectum, 2005, 48, 1220-1227.	0.7	16
41	Symptomâ€association probability between meal ingestion and abdominal pain in patients with irritable bowel syndrome. Does somatization play a role?. Neurogastroenterology and Motility, 2015, 27, 416-422.	1.6	15
42	Incidence and clinical outcomes of intersphincteric abscesses diagnosed by anal ultrasonography in patients with crohn's disease. Inflammatory Bowel Diseases, 2011, 17, 2102-2108.	0.9	14
43	Local regulation of postprandial motor responses in ileal pouches. Gut, 1999, 45, 575-580.	6.1	13
44	Oesophageal acid clearance in patients with systemic sclerosis. European Journal of Gastroenterology and Hepatology, 1996, 8, 205-210.	0.8	12
45	Plasma somatostatin-like immunoreactivity and somatostatin-28 levels in obese men. Journal of Endocrinological Investigation, 1998, 21, 20-23.	1.8	12
46	Single doses of ritodrine delay orocaecal transit in patients with irritable bowel syndrome British Journal of Clinical Pharmacology, 1990, 29, 355-358.	1.1	11
47	Manometric patterns of rat colonic motor activity and defecation. Digestive Diseases and Sciences, 1994, 39, 1968-1973.	1.1	10
48	Oesophageal motor function in chronic intestinal idiopathic pseudo-obstruction: A study with high-resolution manometry. Digestive and Liver Disease, 2018, 50, 142-146.	0.4	10
49	Autonomic control of heart period in duodenal ulcer patients. Autonomic Neuroscience: Basic and Clinical, 2000, 84, 122-129.	1.4	9
50	Intraesophageal pH monitoring during acid infusion in patients with systemic sclerosis. Digestive Diseases and Sciences, 1999, 44, 1716-1720.	1.1	7
51	High spontaneous chromosomal damage in lymphocytes from patients with hereditary megaduodenum. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1995, 348, 33-36.	1.2	5
52	Letter: limitations of defecography among patients with refractory constipation. Alimentary Pharmacology and Therapeutics, 2019, 50, 111-112.	1.9	5
53	Inhibition of pentagastrin-stimulated gastric acid secretion and plasma levels of the new histamine H2-receptor antagonist ramixotidine dihydrochloride (CM 57755) in human volunteers. European Journal of Clinical Pharmacology, 1987, 32, 467-470.	0.8	4
54	Effect of continuous rectal distention on anal resting pressure. Diseases of the Colon and Rectum, 2001, 44, 672-676.	0.7	4

GUIDO BASILISCO

#	Article	IF	CITATIONS
55	Drug side-effects in IBD. Alimentary Pharmacology and Therapeutics, 2002, 16, 1831-1831.	1.9	4
56	Reduced Bone Mineral Density in Chronic Intestinal Idiopathic Pseudo-Obstruction. American Journal of Gastroenterology, 2008, 103, 1579-1581.	0.2	4
57	Seated anorectal manometry during simulated evacuation: A physiologic exercise or a new clinically useful diagnostic test?. Neurogastroenterology and Motility, 2020, 32, e14001.	1.6	4
58	Plasma prolactin, sex steroids and gastrin in human volunteers treated for 2 weeks with therapeutic doses of cimetidine or the new histamine H2-receptor antagonist ramixotidine (CM 57755A). European Journal of Clinical Pharmacology, 1988, 35, 529-534.	0.8	2
59	Intragastric and intraoesophagel pH monitoring in duodenal ulcer patients: effect of the new histamine H2-receptor antagonist ramixotidine. European Journal of Clinical Pharmacology, 1989, 37, 405-407.	0.8	2
60	Fecal Incontinence Induced by Spontaneous Internal Anal Sphincter Relaxation. Diseases of the Colon and Rectum, 2002, 45, 973-976.	0.7	2
61	Effect of rectal distension on abdominal girth. Neurogastroenterology and Motility, 2004, 16, 497-502.	1.6	2
62	Neuromuscular alterations in the dilated ileum of an adult patient with segmental lymphangiectasia. European Journal of Gastroenterology and Hepatology, 2008, 20, 935-938.	0.8	2
63	Magnetic resonance imaging of rectal volume in patients with irritable bowel syndrome. Digestive and Liver Disease, 2011, 43, 529-534.	0.4	2
64	Editorial: symptom improvement does not equal satisfaction with treatment for constipation—authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 910-911.	1.9	2
65	Loperamide and oroâ€caecal transit delay [letter]. British Journal of Clinical Pharmacology, 1986, 22, 371-372.	1.1	1
66	Reproducibiility of sensations induced by rectal distention in patients with irritable bowel syndrome: Role of rectal contractions. Gastroenterology, 2000, 118, A842.	0.6	1
67	Should patients with IBS be submitted to painful rectal distention in clinical practice?. Gastroenterology, 2003, 124, 863.	0.6	1
68	"Pseudotumoral―hepatic pattern in acute alcoholic hepatitis: A case report. World Journal of Gastroenterology, 2009, 15, 4070.	1.4	1
69	OC.08.5: Ultrasound Elasticity Imaging Predicts Therapeutic Outcome in Patients with Crohn'S Disease Treated with Anti-Tumor Necrosis Factor Antibodies. Digestive and Liver Disease, 2017, 49, e98.	0.4	1
70	OC.04.2: Oesophageal Motor Function in Chronic Intestinal Idiopathic Pseudo-Obstruction: A Study with High Resolution Manometry. Digestive and Liver Disease, 2017, 49, e85-e86.	0.4	1
71	Ultrasound Elasticity Imaging Predicts Therapeutic Outcome in Patients with Crohn's Disease Treated with Anti-Tumor Necrosis Factor Antibodies. Gastroenterology, 2017, 152, S606.	0.6	1

#	Article	IF	CITATIONS
73	Internal anal sphincter in patients with fecal incontinence. Gastroenterology, 1990, 98, 1103.	0.6	0
74	Risk factors for first operation in Crohn's disease. Journal of Pediatric Surgery, 1990, 25, 1005.	0.8	0
75	Spontaneous chromosomal fragility in patients with familial visceral myopathy with megaduodenum. Gastroenterology, 1995, 108, A568.	0.6	0
76	Effect of distention rate on rectal accommodation and perception in irritable bowel syndrome (IBS). Gastroenterology, 1998, 114, A718-A719.	0.6	0
77	Increase in abdominal girth during rectal distension. Gastroenterology, 2003, 124, A683-A684.	0.6	0
78	Manometric and ultrasonographic criteria of hereditary proctalgia fugax. Gastroenterology, 2003, 124, A683.	0.6	0
79	OC3.07.3 RECTAL MUCOSAL IMMUNOHISTOCHEMICAL CORRELATES OF PSYCHOLOGICAL AND FUNCTIONAL ALTERATIONS IN IRRITABLE BOWEL SYNDROME (IBS). Digestive and Liver Disease, 2008, 40, S56.	0.4	0
80	PA.157 COMPUTED TOMOGRAPHY ENTEROGRAPHY (CT) AND SMALL BOWEL ULTRASOUND (US) IN ASSESSING ILEAL CROHN'S DISEASE (CD) ACTIVITY. Digestive and Liver Disease, 2008, 40, S132-S133.	0.4	0
81	PA.177 MAGNETIC RESONANCE IMAGING (MRI) OF THE RECTUM AND BOWEL HABIT IN IRRITABLE BOWEL SYNDROME (IBS). Digestive and Liver Disease, 2008, 40, S140.	0.4	0
82	MESENTERIC FAT HYPERTROPHY IN ILEAL CROHN'S DISEASE: DOES IT CONTRIBUTE TO C-REACTIVE PROTEIN PRODUCTION?. Digestive and Liver Disease, 2009, 41, S133.	0.4	0
83	P.32 BOWEL HABIT SUBTYPES IN IRRITABLE BOWEL SYNDROME: THE ROLE OF DIARY CARDS. Digestive and Liver Disease, 2010, 42, S114.	0.4	0
84	P.62 INFLIXIMAB MODULATES MUCOSAL CYTOKINE PROFILE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES. Digestive and Liver Disease, 2010, 42, S125.	0.4	0
85	P.81 IS METHOTREXATE FOR INFLAMMATORY BOWEL DISEASES UNDERUSED IN CLINICAL PRACTICE?. Digestive and Liver Disease, 2010, 42, S132.	0.4	0
86	P.1.14: INFLIXIMAB MODULATES IL23-TH17 AXIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES. Digestive and Liver Disease, 2011, 43, S152-S153.	0.4	0
87	Do Symptoms of Lactose Intolerance Reveal a Somatoform Disorder?. Gastroenterology, 2011, 140, S-94.	0.6	0
88	Infliximab Modulates Il23-TH17 Axis in Patients With Inflammatory Bowel Diseases. Gastroenterology, 2011, 140, S-591.	0.6	0
89	CS15-7. Decrease of IL-17 and Gm-Csf in Intestinal Mucosa of Ibd Patients is Associated With Reduction of CD68+ Macrophages and Clinical Remission in Response to Anti-TNF Therapy. Cytokine, 2011, 56, 104.	1.4	0
90	P.1.228: DO SYMPTOMS OF LACTOSE INTOLERANCE REVEAL A SOMATOFORM DISORDER?. Digestive and Liver Disease, 2011, 43, S223-S224.	0.4	0

#	Article	IF	CITATIONS
91	Amebic colitis in Italy after Christmas. Digestive and Liver Disease, 2012, 44, e8.	0.4	Ο
92	P.14.4 ABDOMINAL PAIN AND EATING IN PATIENTS WITH IRRITABLE BOWEL SYNDROME. ROLE OF SOMATISATION. Digestive and Liver Disease, 2014, 46, S110.	0.4	0
93	Study of somatization in IBS. Neurogastroenterology and Motility, 2015, 27, 741-741.	1.6	Ο
94	Response to Vitton et al Neurogastroenterology and Motility, 2018, 30, e13226.	1.6	0
95	Rectal area as surrogate measure of rectal emptying during MR defecography. Neurogastroenterology and Motility, 2019, 31, e13634.	1.6	0
96	Investigation of anorectal motility. , 2020, , 399-412.		0